IOPtima Reports Successful Long-Term Results in the Use of its Laser System for Treatment of Glaucoma
May 8, 2009
IOPtima, the Israeli developer of a laser-based surgical device for reducing intra ocular pressure (IOP) for the treatment of glaucoma, successfully completed and analyzed the results of its first 12-month follow-up period of human clinical trials conducted in Mexico and India.
IOPtima’s laser-based technology enables eye surgeons to perform a simple and safe surgery and reduce IOP without penetrating the eye membrane.
Study results showed the following results:
- The combined results of the study in Mexico and India demonstrated an average reduction of 43% in IOP from 25.5 mmHg’ pre procedure to 14.6 mmHg’ after 12 months follow-up.
- In addition, the Company’s procedure reduced the number of medications taken by the treated patients from 2.6 medications to 0.6, on average.
- These results reflect a Qualified success, (i.e. IOP of less than 18 mmHg’, regardless of medication) of 95% of those treated in the study, and Complete success, (i.e. IOP of less then 18 mmHg’ with no additional medications), of 67%.
Read the full release.
You might also enjoy...
- QLT Announces Interim Data for Phase 2 Punctal Plug Delivery System Clinical Trial
- Sirion Therapeutics Announces Positive Results from Phase II Trials Evaluating Fenretinide for Treatment of Geographic Atrophy and Receipt of Fast Track Designation from the FDA
- Trabecular Micro-Bypass Implant of Glaukos iStent With Phacoemulsification Helped Reduce IOP
- Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction in Glaucoma Patients
- Can Femtosecond Laser Be Used to Correct Myopia?
Comments
Jump down to form below to submit your own comments
4 Responses to “IOPtima Reports Successful Long-Term Results in the Use of its Laser System for Treatment of Glaucoma”
Trackback URL
http://eyedocnews.com/001092-ioptima-reports-successful-long-term-results-in-the-use-of-its-laser-system-for-treatment-of-glaucoma/trackback/
Have insights to contribute? Please submit your comment below
Subscribe for Free!
i like the idea of no penetrating the ac- hypotony probably much less likely. and the self-stopping technology is sweet. but unfortunately, this is still a bleb-based procedure, so all those problems still bedevil us, namely, late scarring/failure, leaks, infection etc. if this laser is not expensive, it may be nice to have when doing trabs. if expensive, i doubt asc’s buying it when reimbursements keep going down.
Just a historical note — Summit Technology tried this with their excimer laser back in the early days of excimer development. It was called PET (partial excimer trabeculoplasty). It also was self-limiting. They abandoned the project.
Also, note that Ioptima is using a CO2 laser.
I have tried contacting them several times to find out more about their technology, but they refuse to respond.
Irv Arons
actually, one company is advocating using the excimer to do an ab interno trab using the excimer if im not mistaken
We discussed it in the commentary following the ELT writeup, back in March.